The DNA Diagnostics Market is set to surge from USD 13.07 billion in 2024 to USD 21.69 billion by 2030, growing at a CAGR of 8.81%. Key trends driving this growth include the emergence of liquid ...

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

The NBDL represents a transition from observing nature as something external to something that is molecularly intimate.

For decades, a neat story about human origins has floated through textbooks and documentaries: modern humans emerged in East ...

Ansa Biotechnologies Inc., the trusted partner for DNA synthesis, today announced the appointment of Geoff Hamilton as Chief Financial Officer and Chief Business Officer. Mr. Hamilton will report ...

“Cancer cells from patient’s primary tumours that ended up relapsing in the liver or the lung early on adopt cellular states ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Xu, W. , Xing, X. and Cheng, S. (2025) Urine-Based Liquid Biopsy for Detecting Recurrence of Bladder Cancer. International ...

Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine, today announced that ten abstracts have been accepted for presentation at the 2025 San Antonio Breast ...

In a wide-ranging discussion on the future of genomics and cancer diagnostics in India, senior leaders from Strand Life ...